EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling

Victoria Roulstone, Joan Kyula, Elizabeth Appleton, Praveen K Bommareddy, Anton Patrikeev, Sylwia Jones, Linta Kuncheria, Charleen Ml Chan Wah Hak, Shane Foo, Holly Baldock, Amarin Wongariyapak, Isla Leslie und 21 weitere

Journal for ImmunoTherapy of Cancer · 2026-03 · 14 (3) · e013692

DOI: 10.1136/jitc-2025-013692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.03.2026. Verfasst von Victoria Roulstone und 32 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Cancer Research, London, UK victoria.roulstone@icr.ac.uk. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Membrane Proteins, Immunotherapy, Interferons. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Cancer Research UK, Replimune Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antitumor immune responses induced by oncolytic immunotherapy (OI) are often followed by upregulation of programmed death-ligand 1 (PD-L1). As such, the combination of OI with blockade of the programmed cell death protein-1 (PD-1)/PD-L1 axis has demonstrated therapeutic activity in preclinical and clinical trials. The purpose of this study is to understand further the immune-mediated mechanism of interaction between oncolytic viruses and anti-PD-1 therapy.

Methods

Tumor cells and immune cells (splenocytes) were cultured separately, or in co-culture with vusolimogene oderparepvec, an oncolytic herpes simplex virus expressing the fusogenic gibbon-ape leukemia virus-fusogenic membrane glycoprotein protein (GALV) and granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as RP1. Viral replication, interferon (IFN) responses and PD-L1 expression were analyzed using wild-type, IFNAR1, TNFAR1 and STING knockout splenocytes. In vivo studies evaluated immune cell infiltrates into the tumor following RP1 administration with anti-PD-1 therapy.

Results

RP1 replication was evident in tumor cells but not splenocytes. This was also accompanied by upregulated IFN expression in cultured splenocytes that was absent in cultured tumor cells. However, when these cell types were co-cultured, splenocytes mediated an interferon response to RP1 via STING that was transmitted to tumor cells in a non-touch-dependent manner. Tumor cells responded to these input signals via upregulation of cell surface major histocompatibility complex-I and PD-L1 through tumor intrinsic JAK-STAT signaling. In vivo, an IFN signature was observed following intratumoral injection of RP1, both in injected and non-injected tumors, which was further increased when combined with anti-PD-1 therapy. Marked upregulation of PD-L1 was observed in tumors injected with RP1 accompanied by the recruitment of CD11b+Ly6G+neutrophils into the tumor microenvironment, which stained positive for PD-L1.

Conclusion

Overall, the data demonstrate that RP1 remodels the tumor microenvironment through a combination of direct and indirect effects on both tumor and immune cells, resulting in an overall more inflamed phenotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyMembrane ProteinsImmunotherapyInterferonsOncolytic VirusesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAnimalsMiceSTING ProteinHumansSignal TransductioncGAS-STING Signaling PathwayCell Line, TumorFemale

Stichwörter der Autor:innen

Combination therapyImmune Checkpoint InhibitorJAK-STATNeutrophilVirology

Substanzen

Membrane ProteinsSTING ProteinInterferonsProgrammed Cell Death 1 ReceptorSting1 protein, mouseImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • The Institute of Cancer Research, London, UK victoria.roulstone@icr.ac.uk.
  • The Institute of Cancer Research, London, UK.
  • Replimune Inc, Woburn, Massachusetts, USA.
  • Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Förderung

  • NCI NIH HHS
  • Cancer Research UK
  • Replimune Inc

Zitieren

APA

Roulstone, V., Kyula, J., Appleton, E., Bommareddy, P. K., Patrikeev, A., Jones, S., Kuncheria, L., Chan Wah Hak, C. M., Foo, S., Baldock, H., Wongariyapak, A., Leslie, I., Pickering, R., Zierhut, C., Smith, H. G., Mohan, N., Murano, C., Hubbard, L. C., Dean, I., …, & Harrington, K. J. (2026). Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling. Journal for ImmunoTherapy of Cancer, 14(3), e013692. https://doi.org/10.1136/jitc-2025-013692

Vancouver

Roulstone V, Kyula J, Appleton E, Bommareddy PK, Patrikeev A, Jones S, et al. Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling. Journal for ImmunoTherapy of Cancer. 2026;14(3):e013692. doi:10.1136/jitc-2025-013692

BibTeX
@article{Roulstone2026,
  author = {Roulstone, Victoria and Kyula, Joan and Appleton, Elizabeth and Bommareddy, Praveen K and Patrikeev, Anton and Jones, Sylwia and Kuncheria, Linta and Chan Wah Hak, Charleen Ml and Foo, Shane and Baldock, Holly and Wongariyapak, Amarin and Leslie, Isla and Pickering, Robert and Zierhut, Christian and Smith, Henry G and Mohan, Nitya and Murano, Carmen and Hubbard, Lisa C and Dean, Isaac and Patin, Emmanuel Christian and Gkantalis, Jim and Mansfield, David and Pedersen, Malin and McLaughlin, Martin and Goicoechea, Maria and Layzell, Scott and Mannion, Jonathan and Fernando, Winnie and Meier, Pascal and Vile, Richard and Melcher, Alan and Coffin, Robert S and Harrington, Kevin J},
  title = {Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {e013692},
  doi = {10.1136/jitc-2025-013692}
}
Kostenlos starten →